drugset / Trial / NCT01915108
Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal
RandomizedParallel-groupSingle-blindPrevention
Summary
This study was designed to determine the optimal dose of remifentanil that can prevent the complications associated with the removal of LMA without delaying emergence.
Timeline
- Start
- 2012-07
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Remifentanil | Small molecule | 0.5 ng/ml | — |
| Comparator | Remifentanil | Small molecule | 1 ng/ml | — |
| Comparator | Remifentanil | Small molecule | 1.5 ng/ml | — |